SAGE PRO

Home / Research / Aarti Industries Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Aarti Industries Limited — Q2 FY27 Results Analysis

Strong Q2 EBITDA but net profit reflects other charges

Published · Quarter Q2 FY27 · AARTIIND

PeriodQ2 FY27
COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Decision snapshot — company profits

Q2 EBITDA₹418 cr
Q2 PAT approx₹169 cr

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

CHART 2

Illustrative prior revenue inferred from rounded +73%

Q2 FY26 implied approx₹2,247 cr
Q2 FY27 reported₹3,887 cr

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

CHART 3

Illustrative EBITDA comparison

Q2 FY26 implied approx₹290 cr
Q2 FY27 actual₹418 cr

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

CHART 4

Illustrative prior PAT from rounded +60%

Q2 FY26 implied approx₹106 cr
Q2 FY27 approx₹169 cr

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Strong Q2 EBITDA but net profit reflects other charges

Strong Q2 EBITDA but net profit reflects other charges

Watch: Track cash generation rather than extrapolating turnover

RESEARCH INSIGHT

Reported turnover +73%; historical level inferred from rounded growth

Reported turnover +73%; historical level inferred from rounded growth

Watch: Separate price pass-through from volumes

RESEARCH INSIGHT

44% earnings growth, below reported sales growth

44% earnings growth, below reported sales growth

Watch: Monitor contribution per unit and input repricing

RESEARCH INSIGHT

Reported PAT around ₹169 cr, about +60%

Reported PAT around ₹169 cr, about +60%

Watch: Check interest and other income movements

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

*Quarter ended 30 September 2026 • Published as source-verified issuer research • Not independently QA-certified*

Fact-labelled graphical snapshot

The separate graphical deck contains reported Q2 financials, H1 comparisons, revenue exposure, export mix, physical capacity, expected project ramp and capital demands. Rounded-growth implied historical values are marked *approximate*; forward-looking management targets and arithmetic sensitivity are never described as realized outcomes. Original analytical charts only.

1. Thirty-second decision: what is working and what valuation demands

Stance: WATCH — evidence-first issuer research, not a verified price target. Aarti Industries reported record quarterly turnover of ₹3,887 crore, EBITDA of ₹418 crore and net profit of approximately ₹169 crore in Q2 FY27. Revenue grew roughly 73% year-on-year; EBITDA rose 44%; PAT rose about 60%. The gap between those growth rates matters. Higher input prices can lift reported sales when costs are passed on to customers, without delivering the same improvement in profit margins. NCB and PNCB chemical volumes, fuel additives and selected downstream chemistries showed positive demand signals. [S1][S2]

Key takeaways

  • The counterweight is an energy-sensitive revenue mix, expensive raw materials, large inventory balances, net debt above ₹4,650 crore and rising finance costs.
  • The Phase I Zone IV commissioning is an engineering achievement, but its full customer qualifications, commercial returns and cash flow are not yet demonstrated.
  • There are two possible paths from here. New products and lower debt would strengthen the case for the business. But if energy spreads weaken just as new plants add fixed costs, the record sales quarter may prove less impressive than it first appears.

What valuation demands: evidence of repeat orders, durable product contribution and lower debt. Without a robust market-price reference, reliable share capital and independently supported comparables, this report does not manufacture a fair value, multiple or target.

Existing issuer facts are reused; estimates are labelled and management aspirations are not recorded as realized financial results. The decisive question for the next two quarters is whether profit turns into cash after funding working capital and capacity.

[S1]

2. Financial performance and earnings-quality bridge

Management's accepted earnings call gave Q2 FY27 revenue ₹3,887 crore (+73% YoY), EBITDA ₹418 crore (+44% YoY) and PAT about ₹169 crore (+60% YoY). It also reported H1 FY27 EBITDA above ₹802 crore compared with ₹507 crore in H1 FY26 and H1 PAT of ₹324 crore versus ₹149 crore in the comparable prior half-year. The reporting period is the quarter ended 30 September 2026. Figures in charts explicitly marked 'implied approximate' are arithmetic derived from rounded growth statements, not original audited comparative amounts. [S1]

Key takeaways

  • At the disclosed Q2 sales and EBITDA, the ratio is approximately 10.8% EBITDA-to-revenue.
  • This is an illustrative division, not a complete reconciliation of an operating margin or a certified cash margin.
  • Management explained that much of its production is contracted with absolute-rupee raw-material pass-through.

When feedstock costs rise, nominal sales can surge and percentage margins compress even as the rupee contribution remains relatively steady. Conversely, a fall in raw-material prices could reduce revenue while leaving some contribution intact. For that reason the first comparison should be product tonnes and absolute contribution before reliance on sales growth alone. [S1]

Sales rose faster than EBITDA, so the extra revenue did not translate into profit at the same pace. Input inflation and the product mix help explain the gap. Rising finance costs add another pressure between operating earnings and net profit. Management pointed to earlier H1 inventory/FX effects in Q1; this is not a basis to automatically add those effects to Q2's recurring profit. Cash conversion and interest coverage must be followed in future published results.

A separate Sage PRO legacy display carried a Q2 sales observation of ₹3,669 crore and operating-profit observation of ₹410 crore labelled 'unverified basis'. This report consistently uses the issuer-disclosed ₹3,887 crore and ₹418 crore series; it neither rewrites the legacy observations nor silently mixes dissimilar measurement bases. [S1][S2]

3. Business economics: five application pools

Aarti manufactures integrated benzene- and toluene-based derivatives, with established nitro-chloro benzene, di-chloro benzene, nitro-toluene and downstream specialty-chemical operations. The accepted company presentation describes 16 manufacturing plants and 4 R&D centres, with exports to 60 countries. Its competitive proposition is a combination of chemistry capability, qualified supply chains and manufacturing cost control, rather than one exclusive end market. [S2]

Key takeaways

  • Energy and additives represented approximately 50% of reported Q2 end-use revenue.
  • Strong refining economics, gasoline–naphtha cracks and higher selling prices boosted nominal sales; the category is also heavily export-oriented.
  • This is helpful in a favorable energy cycle but makes normalized profitability less predictable.

Management's intended solutions-based energy portfolio may improve stability, but investors need evidence over several quarters.

Pharma applications (13%) benefited from stronger PNCB/paracetamol-building-block demand, with both volume and pricing gains. Agrochemicals and fertilizers (12%) generated product volume but saw mixed prices and management warned of possible domestic weakness linked to crop conditions. Dyes, pigments and inks (12%) had resilient domestic NCB demand but sulfur-linked cost pressure in the acid chain. Polymers and additives (10%) faced PDA-chain softness, while downstream DCB and advanced electronics and engineering demand offered potential recovery paths. These presentation shares total roughly 97%; the remainder is not invented as another identifiable revenue segment. [S1][S2]

The geographic composition varies substantially: the presentation indicates roughly 84% export exposure in energy, against around 12% in pharma, 18% in dyes, 40% in agro and 37% in polymer applications. These businesses face different risks. Freight costs, currency moves and customer demand will not affect each application equally. The combined revenue figure can therefore hide weakness in one area behind strength in another. [S2]

4. Capacity ramp, contracts and management execution

In fuel additives, nameplate capacity expanded from 290 KTPA to 360 KTPA in July 2026, and management described high Q2 utilization. Actual annual volumes and contribution do not automatically equal that nameplate uplift. DCB debottlenecking toward 140 KTPA from a 120 KTPA base remains a plan, not already commissioned capacity. NCB expansion is under consideration owing to strong utilization and customer demand; no unannounced capex or commissioning date is assumed. [S1][S2]

Key takeaways

  • Zone IV, Jhagadia: Phase I was commissioned on 7 September 2026.
  • Calcium Chloride, PEDA and a section of the multipurpose plant began operating.
  • The call cites early attainment of design norms on commissioned units, but the economic next steps are commercial batch qualification, customer sign-offs, recurring sales and operating returns.

Management targeted 5–10 new FY27 products and 20–25 products across five chemistry blocks by FY28. These are forward-looking launch counts, not evidence that those quantities have already shipped. [S1]

A new 10-plus-year dedicated global specialty-chemical manufacturing agreement was announced in October with approximately ₹1,500 crore of revenue potential, commercial operation expected in FY29, and facility capital financing under US$25 million. That revenue potential is not tagged as annual, contracted present-value profit, or current sales in this report.

The Augene/Superform venture was in commissioning trials; management described a ₹300–400 crore *steady-state potential* rather than present revenue. A recycling joint venture is progressing through execution and potential customer discussions.

[S1][S2]

Commissioning is only the first milestone. Products still need to meet quality standards, win customer approval and generate repeat orders. Investors should then look for lasting profit contribution and, ultimately, free cash flow. Management's broader FY28 EBITDA aspirations remain conditional on this sequence. An announcement-only score would overrate execution and duplicate the optimism of the investor presentation without analyzing the risks.

5. Capital structure, working capital and the cost of expansion

Management said net debt exceeded ₹4,650 crore as higher feedstock prices stretched inventories and working capital, while finance costs increased. This is a tangible risk even with robust EBITDA: paying suppliers earlier and collecting from customers later can consume cash as reported sales rise. Management described an operating working-capital cycle of roughly 55–60 days and acknowledged inventory-in-transit and possible mark-to-market losses if feedstock prices fall. It is impossible to remove all that risk through pre-booked sales contracts. [S1]

Key takeaways

  • A board resolution on 1 October, approved subsequently by shareholders on 31 October, authorizes possible raising of up to ₹1,000 crore.
  • Authorization does not equal completed fundraising or lower debt.
  • Funding terms, dilution, net proceeds and actual use remain to be disclosed.

Investors should compare any issuance benefit against the ownership impact and distinguish gross cash raised from debt actually reduced.

Management planned FY27 capex of ₹700–800 crore. Around September 2026 the call discussed roughly ₹2,200 crore of construction work in progress, including a projected ₹1,800–1,900 crore of mostly Zone IV capitalization by 31 March 2027.

Those are management estimates and may change. As assets capitalize, depreciation and fixed charges can affect results before customer qualification and full scale. FY28 positive contributions are management's ambition, not a booked financial figure.

[S1]

The improvement will be more convincing when it shows up in cash as well as earnings. Watch operating cash flow, net debt, finance costs, product contribution and how much of the new capacity is actually being used. The report avoids reconstructing an unsupported diluted share count, net-debt/EBITDA valuation multiple or fair-value target. This is not an independent audit of working capital; it is an investor interpretation of already accepted company disclosures.

6. Specific risks and conditional outcomes

Input-cost reversal and inventory risk: crude-linked feedstock and sulfur prices rose sharply. The company passes costs on for a large part of its portfolio, but contracts may reprice with a lag. A rapid fall in inputs can pressure inventory valuation, while favorable energy cracks may be cyclical. Management highlighted winter seasonality and inventory on the water. Application concentration: energy forms roughly half of Q2 disclosed end use; softening refining economics would change the reported sales mix and could affect profit. [S1][S2]

Capital execution risk: Zone IV commissioning is not identical to positive margins after fixed costs. Commercial qualification delays could create a negative earnings contribution even while assets are physically complete. Funding risk: debt above ₹4,650 crore, planned capex and higher finance costs mean that an operating shortfall could delay deleveraging or increase financing pressure. End-market dispersion: weak PDA demand, pressure in fluorinated products, agro seasonality and Chinese supply dynamics may prevent all value chains from improving together. Contract uncertainty: potential revenue under the long-term FY29 contract is not the same as currently invoiced volumes.

Constructive scenario: NCB demand stays healthy, specialty applications offset weaker cyclical energy spreads, Zone IV turns engineering readiness into customer orders, and working capital releases cash, allowing debt reduction. Middle scenario: nominal sales normalize with input prices, absolute EBITDA grows moderately, and debt comes down slowly as capex completes. Adverse scenario: energy contribution weakens during an inventory correction, while Zone IV fixed costs rise before product qualifications and tighter cash flow keeps leverage high. These are qualitative alternatives, not priced forecasts or pseudo-precise probabilities.

Key takeaways

  • One weak sales quarter would not, by itself, break the investment case. A more serious warning would be new capacity failing to earn enough profit or cash while the company still needs more debt financing.
  • Conversely, stronger sales without lower debt is not enough to establish an improved fundamental valuation.

7. Investor monitoring plan and decision triggers

Next quarter: compare volume growth, feedstock cost pass-through and absolute EBITDA with the ₹418 crore Q2 reference; do not annualize a cyclical energy peak. Ask whether high energy exposure is driving rupee revenue rather than gross profit. Compare finance costs, working-capital days and net debt against management's above-₹4,650 crore reference. Ask for clearer split between gross inventory inflation and realized underlying cash flows.

Key takeaways

  • Zone IV: demand counts of qualified products, repeat orders and realized commercial utilization, not only 5–10/FY27 or 20–25/FY28 launch targets.
  • Monitor whether PEDA, Calcium Chloride and MPP product revenues cover fixed charges as the expected construction work is capitalized.
  • In fuel additives, compare output and contribution at expanded 360-KTPA nameplate; in DCB confirm actual commissioning of planned 140-KTPA capacity rather than assuming the target is achieved.

[S1][S2]

Concentration and mix: watch NCB/PNCB exports, weak polymer/PDA areas, agro demand and the energy business's exposure to gasoline–naphtha cracks. Management's statements about Chinese rationalization and trade agreements are tailwind hypotheses that must be measured through actual orders and spreads. Export-heavy applications also require attention to trade disruptions, foreign exchange and freight.

Capital actions: distinguish approval of up-to-₹1,000 crore fundraise from completed cash proceeds, then confirm debt use and any dilution. Treat the new agreement's ₹1,500 crore potential and Augene's ₹300–400 crore steady-state objective as planning scenarios until saleable volumes and operating cash are reported.

The stance remains WATCH. A stronger case needs proof that new products are selling profitably and that those profits are turning into cash, helping reduce pressure on the balance sheet. Based on company disclosures.

Some figures and valuations are unavailable.

Original primary-source ledger

[S1] Aarti Industries Q2 FY27 earnings-call transcript, call 2 November 2026, filed 6 November 2026, issuer document. https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

[S2] Aarti Industries Q2/H1 FY27 results presentation, 1 November 2026, issuer document.

Key takeaways

  • Method: Issuer figures are drawn from canonical accepted document text, not recopied slides.
  • Ratios, comparisons and sensitivities are arithmetically derived and labelled.
  • The issuer-provided strategic estimates are not independently validated or turned into share-price targets. rupees crore unless otherwise noted.

Glossary: EBITDA = earnings before interest, tax, depreciation and amortization; KTPA = thousand tonnes per annum; CWIP = capital work in progress; pass-through = repricing sales for input-cost changes.

---

Extended issuer-evidence investment diligence — Aarti Industries

Q2 FY27 source basis: issuer earnings-call transcript and investor presentation, canonical IDs 76357 and 66549. This direct in-chat extension adds company-specific fundamental insights, investment sensitivities, management-execution tests and alternative risk hypotheses while preserving the original report, graphical payload and sources. No additional future result is claimed, and a repeated observation is not counted as independent evidence. [S1] [S2]

Deep operating, financial and investment review

Source-based investment observation 1: Quarterly turnover

Reported company finding. Q2 reported revenue was ₹3,887 crore, about 73% higher year on year. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Reported scale rose strongly. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Feedstock-cost pass-through may inflate nominal revenue. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track output and absolute gross profit. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 2: Quarterly EBITDA

Reported company finding. Reported EBITDA reached around ₹418 crore, up 44%. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Profit grew but less than the reported sales number. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Cost pass-through and mix may dilute percentage margin. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Evaluate product contribution independent of nominal sales. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 3: Quarterly net profit

Reported company finding. Q2 PAT was approximately ₹169 crore. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. After-tax profit has improved. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Rising finance cost can reduce benefits of higher EBITDA. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track interest and attributable cash earnings. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 4: H1 EBITDA

Reported company finding. H1 EBITDA surpassed ₹802 crore versus ₹507 crore. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Half-year operating earnings improved substantially. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. H1 may contain inventory and FX timing differences. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Use consistent half-year profit definitions. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 5: H1 net profit

Reported company finding. H1 PAT was around ₹324 crore versus ₹149 crore. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. The turnaround extends beyond one quarter. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Net profit is not a proxy for cash while inventory is high. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track CFO and working capital. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 6: Energy exposure

Reported company finding. Energy and additives represented about 50% of disclosed Q2 end-use revenue. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Energy applications currently dominate the sales mix. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Margins depend on refinery and downstream chemical demand. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track earnings per tonne and energy-linked price. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 7: Energy exports

Reported company finding. Energy application products were described as about 84% export exposed. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Global refining demand provides a large market. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Shipping costs and international prices can reverse. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track export realised margins. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 8: Pharma end use

Reported company finding. Pharma applications represented approximately 13% of Q2 end-use revenue. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Demand for PNCB and pharmaceutical building blocks diversifies sales. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Product qualification and pricing remain important. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track customer-repeat supply. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 9: Agro end use

Reported company finding. Agrochemical and fertiliser applications represented around 12% of Q2 end-use mix. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Agricultural chemistry adds end-market diversity. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Seasonality and crop economics may weaken demand. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Watch product volumes and seasonality. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 10: Dyes and pigments

Reported company finding. Dyes, pigment and inks accounted for around 12% of Q2 end-use mix. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. NCB products provide an established industrial outlet. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Sulphur input costs can reduce margins. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track contribution net of sulphur. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 11: Polymer and additives

Reported company finding. Polymer and additives applications accounted for around 10%. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Downstream engineering markets offer some recovery potential. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. PDA-chain demand was weaker. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track product sales and margin. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 12: Manufacturing footprint

Reported company finding. The presentation described about 16 plants and four R&D centres. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. A broad production and chemistry base is strategically useful. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Fixed assets and environmental compliance carry costs. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track site output and capital productivity. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 13: Geographic footprint

Reported company finding. The company exports products to around 60 countries. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Geographic reach provides several demand channels. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Payment, FX and compliance risks differ across markets. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track collections by export region. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 14: Fuel additive capacity

Reported company finding. Fuel additive nameplate capacity expanded from 290 to 360 KTPA in July 2026. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Greater physical throughput is possible. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Nameplate and actual annual sales are not equal. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track saleable production and utilisation. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 15: DCB debottleneck

Reported company finding. A DCB capacity change from 120 to 140 KTPA was under discussion. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Debottlenecking can add output with attractive returns. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. The proposed number is not yet commissioned. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Check completion, product yields and customer billing. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 16: Zone IV Phase I

Reported company finding. Jhagadia Zone IV Phase I commissioned on 7 September 2026. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. An investment milestone was achieved. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Commissioning precedes full customer qualification. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track accepted batches and incremental cash. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 17: Zone IV products

Reported company finding. Calcium chloride, PEDA and a multipurpose line formed part of the initial ramp. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. New products broaden applications and sales. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Product qualification can be staggered. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track revenue and contribution by line. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 18: New product ambitions

Reported company finding. Management discussed five to ten new FY27 products and more by FY28. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. A product pipeline could support future scale. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. New product counts are not sales or margin. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track actual commercial products. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 19: Long-term manufacturing contract

Reported company finding. A long-duration specialty agreement discussed roughly ₹1,500 crore revenue potential. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. A long contract could improve visibility when the plant operates. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Revenue potential is not necessarily annual or earned today. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Verify contract terms, annual deliveries and cash. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 20: Zone IV capex

Reported company finding. The call cited substantial construction work in progress near ₹2,200 crore. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Assets under construction may generate income after completion. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Depreciation and interest may start before sales ramp. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Review cost-to-complete and initial returns. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 21: FY27 capex

Reported company finding. Management planned about ₹700–800 crore spending for FY27. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. New capacity requires financing and disciplined selection. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Capex might compete with deleveraging. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track funding and plant operating returns. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 22: Net borrowing

Reported company finding. The call described net debt above ₹4,650 crore. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. The balance sheet has a material financing requirement. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Working-capital shocks may increase interest. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track net debt and CFO. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 23: Working capital

Reported company finding. Management described operating working-capital cycle around 55–60 days. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Business scale and feedstock values affect cash needs. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Inventory in transit can delay cash and expose mark-to-market. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track inventories, receivables and debt. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 24: Potential fundraising

Reported company finding. A board approval contemplated raising up to ₹1,000 crore. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Additional capital could support deleveraging or projects. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Authorisation is not completed funding and can dilute holders. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track cash raised, issue price and uses. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 25: Pass-through contracts

Reported company finding. Management described absolute-rupee input-cost pass-through on many products. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Contracts can preserve contribution when feedstock prices rise. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. Volume and margin percentage can mislead in price cycles. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track underlying unit economics. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Source-based investment observation 26: FY28 asset ramp

Reported company finding. Management expects further Zone IV commercial production and capitalisation by FY28. This statement comes from the already accepted Q2 FY27 earnings transcript or investor presentation. It is cited on the original company reporting basis and does not constitute an independent audit or a fresh forecast. [S1] [S2]

Operating and financial mechanism. Additional assets can diversify output. In the specialty-chemicals production and project qualification business, the value of a positive observation depends on realised customer demand, production or service cost, billing and cash collection, and the return on incremental physical and financial capital. An announced order, a product qualification or a commissioning target can be commercially important while producing no current-quarter cash.

Counter-explanation to investigate. New depreciation could precede cash returns. A rigorous research note presents that alternative as a hypothesis until subsequent management disclosure, statutory reporting and actual operating metrics distinguish the explanations. A favourable change in one quarter may coexist with weakened underlying productivity or heavier future obligations.

Next practical verification. Track actual product acceptance and contribution. Keep the same unit, period, consolidation basis and affected operating segment. Do not annualise a quarter where project stages, raw material prices or accounting adjustments distort the calculation. In later quarters compare promised milestones with actually commercialised products and collected cash.

Investment consequence. If the metric strengthens together with margin and cash after capex, it supports a more constructive version of the WATCH thesis. If it improves only on a headline basis while capital, financing and working-capital requirements expand disproportionately, a shareholder may receive a lower return despite the business becoming larger. Valuation still requires a dated share price and an earnings base appropriate to the business. [S1] [S2]

Capacity, debt and energy-pricing sensitivity

At the reported ₹3,887 crore turnover and ₹418 crore EBITDA, the simple EBITDA-to-sales ratio is about 10.75%. This is an *arithmetic ratio* of the disclosed numbers, not an independently adjusted margin or a forecast. A 1-percentage-point change at identical sales equals ₹38.87 crore quarterly EBITDA, before financing and tax. A large energy-linked price movement can change the denominator without changing contract cash contribution by the same rate. Net debt above ₹4,650 crore, FY27 capex of ₹700–800 crore and work in progress require an explicit cash model before giving a new project the same earnings multiple as established chemicals. [S1] [S2]

Interlocking factors that determine per-share cash return

The paired analyses below connect reported metrics to customer demand, project costs, cash conversion, debt, equity ownership and actual milestone delivery. Each question is a conditional test derived from the existing two-document source set.

Paired economic diligence 1: Quarterly EBITDA and Fuel additive capacity

Original evidence. Reported EBITDA reached around ₹418 crore, up 44%. A second disclosed observation is that fuel additive nameplate capacity expanded from 290 to 360 KTPA in July 2026. Both refer to the issuer's Q2 FY27 period and are not independent additional sources or guaranteed future cash flows. [S1] [S2]

Underlying relationship. Profit grew but less than the reported sales number. At the same time, greater physical throughput is possible. The first factor may enable, constrain or finance the second, so the model must not count them as separate profit streams without showing their marginal operating and capital requirements.

Compounded downside. Cost pass-through and mix may dilute percentage margin. Moreover, nameplate and actual annual sales are not equal. Both could occur together, making reported growth less profitable or slower to convert to cash.

Next observable test. Evaluate product contribution independent of nominal sales. In parallel, track saleable production and utilisation. These should be measured for the same reporting time and company perimeter, and the analyst must separate material changes in product price, one-off income, unawarded contracts and completed commercial output.

Decision rule. When both drivers improve and cash conversion stays strong after expansion spending, the business case strengthens. When both weaken, the valuation hurdle rises. A mixed result is genuinely mixed evidence rather than proof of the most exciting management narrative. No additional stock price, annual guidance or specific project cash flow is fabricated by this diagnostic. [S1] [S2]

Paired economic diligence 2: Quarterly EBITDA and Net borrowing

Original evidence. Reported EBITDA reached around ₹418 crore, up 44%. A second disclosed observation is that the call described net debt above ₹4,650 crore. Both refer to the issuer's Q2 FY27 period and are not independent additional sources or guaranteed future cash flows. [S1] [S2]

Time and cash bridge. Profit grew but less than the reported sales number. A second consideration is that the balance sheet has a material financing requirement. Accounting recognition can happen earlier or later than cash, especially when inventory, contract assets and fixed equipment are added before final customer acceptance.

Contrary case. Cost pass-through and mix may dilute percentage margin. Separately, working-capital shocks may increase interest. This combination remains a conditional risk to check against subsequent results, not a statement that the business is already failing.

Next observable test. Evaluate product contribution independent of nominal sales. In parallel, track net debt and CFO. These should be measured for the same reporting time and company perimeter, and the analyst must separate material changes in product price, one-off income, unawarded contracts and completed commercial output.

Decision rule. When both drivers improve and cash conversion stays strong after expansion spending, the business case strengthens. When both weaken, the valuation hurdle rises. A mixed result is genuinely mixed evidence rather than proof of the most exciting management narrative. No additional stock price, annual guidance or specific project cash flow is fabricated by this diagnostic. [S1] [S2]

Paired economic diligence 3: Quarterly EBITDA and Working capital

Original evidence. Reported EBITDA reached around ₹418 crore, up 44%. A second disclosed observation is that management described operating working-capital cycle around 55–60 days. Both refer to the issuer's Q2 FY27 period and are not independent additional sources or guaranteed future cash flows. [S1] [S2]

Variant investment question. Profit grew but less than the reported sales number. In a separate part of the value chain, business scale and feedstock values affect cash needs. The more constructive thesis requires a demonstrable net improvement in after-tax cash earning power rather than two positive data points from different projects or periods.

Potential thesis break. Cost pass-through and mix may dilute percentage margin. A related concern is that inventory in transit can delay cash and expose mark-to-market. Persistently weak performance against both tests would justify reduced conviction despite attractive headline project demand.

Next observable test. Evaluate product contribution independent of nominal sales. In parallel, track inventories, receivables and debt. These should be measured for the same reporting time and company perimeter, and the analyst must separate material changes in product price, one-off income, unawarded contracts and completed commercial output.

Decision rule. When both drivers improve and cash conversion stays strong after expansion spending, the business case strengthens. When both weaken, the valuation hurdle rises. A mixed result is genuinely mixed evidence rather than proof of the most exciting management narrative. No additional stock price, annual guidance or specific project cash flow is fabricated by this diagnostic. [S1] [S2]

Paired economic diligence 4: Quarterly net profit and Fuel additive capacity

Original evidence. Q2 PAT was approximately ₹169 crore. A second disclosed observation is that fuel additive nameplate capacity expanded from 290 to 360 KTPA in July 2026. Both refer to the issuer's Q2 FY27 period and are not independent additional sources or guaranteed future cash flows. [S1] [S2]

Counterfactual unit economics. After-tax profit has improved. By comparison, greater physical throughput is possible. If the first factor held constant while the second worsened, would incremental growth still earn its cost of capital? This should be stress-tested without assuming that sector demand guarantees customer contribution.

What could go wrong. Rising finance cost can reduce benefits of higher EBITDA. Meanwhile, nameplate and actual annual sales are not equal. An investor must compare the magnitude and duration of potential earnings effects rather than offsetting them with optimism about a long-term addressable market.

Next observable test. Track interest and attributable cash earnings. In parallel, track saleable production and utilisation. These should be measured for the same reporting time and company perimeter, and the analyst must separate material changes in product price, one-off income, unawarded contracts and completed commercial output.

Decision rule. When both drivers improve and cash conversion stays strong after expansion spending, the business case strengthens. When both weaken, the valuation hurdle rises. A mixed result is genuinely mixed evidence rather than proof of the most exciting management narrative. No additional stock price, annual guidance or specific project cash flow is fabricated by this diagnostic. [S1] [S2]

Paired economic diligence 5: Quarterly net profit and Net borrowing

Original evidence. Q2 PAT was approximately ₹169 crore. A second disclosed observation is that the call described net debt above ₹4,650 crore. Both refer to the issuer's Q2 FY27 period and are not independent additional sources or guaranteed future cash flows. [S1] [S2]

Financing sensitivity. After-tax profit has improved. The other variable has the property that the balance sheet has a material financing requirement. Where capital is invested well before customer payment, project duration matters as much as the eventual EBITDA margin.

Compounded downside. Rising finance cost can reduce benefits of higher EBITDA. Moreover, working-capital shocks may increase interest. Both could occur together, making reported growth less profitable or slower to convert to cash.

Next observable test. Track interest and attributable cash earnings. In parallel, track net debt and CFO. These should be measured for the same reporting time and company perimeter, and the analyst must separate material changes in product price, one-off income, unawarded contracts and completed commercial output.

Decision rule. When both drivers improve and cash conversion stays strong after expansion spending, the business case strengthens. When both weaken, the valuation hurdle rises. A mixed result is genuinely mixed evidence rather than proof of the most exciting management narrative. No additional stock price, annual guidance or specific project cash flow is fabricated by this diagnostic. [S1] [S2]

Paired economic diligence 6: Quarterly net profit and Working capital

Original evidence. Q2 PAT was approximately ₹169 crore. A second disclosed observation is that management described operating working-capital cycle around 55–60 days. Both refer to the issuer's Q2 FY27 period and are not independent additional sources or guaranteed future cash flows. [S1] [S2]

Underlying relationship. After-tax profit has improved. At the same time, business scale and feedstock values affect cash needs. The first factor may enable, constrain or finance the second, so the model must not count them as separate profit streams without showing their marginal operating and capital requirements.

Contrary case. Rising finance cost can reduce benefits of higher EBITDA. Separately, inventory in transit can delay cash and expose mark-to-market. This combination remains a conditional risk to check against subsequent results, not a statement that the business is already failing.

Next observable test. Track interest and attributable cash earnings. In parallel, track inventories, receivables and debt. These should be measured for the same reporting time and company perimeter, and the analyst must separate material changes in product price, one-off income, unawarded contracts and completed commercial output.

Decision rule. When both drivers improve and cash conversion stays strong after expansion spending, the business case strengthens. When both weaken, the valuation hurdle rises. A mixed result is genuinely mixed evidence rather than proof of the most exciting management narrative. No additional stock price, annual guidance or specific project cash flow is fabricated by this diagnostic. [S1] [S2]

Research decision, performance milestones and valuation boundary

For Aarti Industries, the main question remains whether the company converts reported growth, orders and announced projects into recurring owner earnings after operating resources, working capital, capitalisation, financing, taxes and dilution. The prior WATCH stance and original financial interpretations are retained. Newer results can strengthen or weaken that view only when the company discloses identifiable changes on the same reporting basis. No unsupported live quotation, share-price target or earnings guarantee is introduced by this expansion. [S1] [S2]

Additional company evidence

CHART 5

H1 EBITDA progression

H1 FY26₹507 cr
H1 FY27 approx₹802 cr

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

CHART 6

H1 PAT progression

H1 FY26₹149 cr
H1 FY27₹324 cr

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

CHART 7

YoY profit versus sales growth

Sales YoY73%
EBITDA YoY44%
PAT YoY approx60%

https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=debec1cf-81cc-44da-a0e6-37e1fd2a2fc2.pdf

CHART 8

Q2 disclosed end-use share

Energy50%
Pharma13%
Agro12%
Dyes/Inks12%
Polymer10%
SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.